Renaissance Capital logo

Eleven Biotherapeutics Priced, Nasdaq: EBIO

Clinical-stage biotech developing protein therapeutics to treat dry eye diseases.

Industry: Health Care

First Day Return: +8.5%

Industry: Health Care

Clinical-stage biotech developing protein therapeutics to treat dry eye diseases.
more less
IPO Data
IPO File Date 12/30/2013
Offer Price $10.00
Price Range $13.00 - $15.00
Offer Shares (mm) 5.0
Deal Size ($mm) $50
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 02/05/2014
Offer Price IPO Intelligence Only
Price Range IPO Intelligence Only
Offer Shares (mm) IPO Intelligence Only
Deal Size ($mm) $50
Lock-Up Date IPO Intelligence Only
Street Research IPO Intelligence Only
Underwriters
IPO Intelligence Only
Company Data
Headquarters Cambridge, MA, United States
Founded 2008
Employees at IPO 16
Website www.elevenbio.com

Eleven Biotherapeutics (EBIO) Performance